Literature DB >> 29121799

Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.

Keun Ha Park1, Dong Ryun Gu1,2, Su Hyun Jin2, Chi-Su Yoon3, Wonmin Ko3, Youn Chul Kim3, Seoung Hoon Lee1,2,4.   

Abstract

Puerariae radix, the dried root of Pueraria lobate Ohwi, is known to prevent bone loss in ovariectomized mice; however, the precise molecular mechanisms are not understood. In this study, we investigated the effects and underlying mechanisms of action of Puerariae radix extract (PRE) on receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis. PRE dose-dependently inhibited osteoclast differentiation and formation, decreased the bone-resorbing activity of osteoclasts, and downregulated the expression of osteoclast differentiation marker genes. The expression of osteoclastogenic factors produced by PRE-treated osteoblasts such as RANKL, macrophage colony-stimulating factor (M-CSF), and osteoprotegerin (OPG) was comparable to that of untreated (control) cells. However, the formation of osteoclasts via bone marrow cell and calvaria-derived osteoblast co-cultures was suppressed by PRE treatment. Therefore, the inhibitory effects of PRE on osteoclastogenesis clearly targeted osteoclasts, but not osteoblasts. PRE treatment considerably reduced RANKL-induced mitogen-activated protein kinases (MAPKs) activity, especially c-Jun N-terminal kinase, in osteoclast precursor cells. In addition, PRE markedly suppressed cAMP response element-binding protein (CREB) activation and the induction of peroxisome proliferator-activated receptor gamma coactivator 1β (PGC1β), which stimulate osteoclastogenesis - an effect that was not observed for puerarin and 17-β estradiol. Finally, PRE treatment significantly repressed the expression of c-Fos and the nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), which is a master transcription factor for osteoclastogenesis in vitro and in vivo. Overall, these results strongly suggest that PRE is an effective inhibitor of RANKL-induced osteoclastogenesis and may be a potent therapeutic agent for bone-related diseases such as osteoporosis, rheumatoid arthritis, and periodontitis.

Entities:  

Keywords:  Bone Disease; CREB; NFATc1; Osteoclast; PGC1β; Pueraria lobate; Puerariae radix

Mesh:

Substances:

Year:  2017        PMID: 29121799     DOI: 10.1142/S0192415X17500938

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  9 in total

1.  Neobavaisoflavone Inhibits Melanogenesis through the Regulation of Akt/GSK-3β and MEK/ERK Pathways in B16F10 Cells and a Reconstructed Human 3D Skin Model.

Authors:  Da Eun Kim; Bo Yoon Chang; Sang Ok Ham; Youn Chul Kim; Sung Yeon Kim
Journal:  Molecules       Date:  2020-06-09       Impact factor: 4.411

2.  Puerarin inhibits the osteoclastogenesis by inhibiting RANKL-dependent and -independent autophagic responses.

Authors:  Guoyou Zhang; Yu Wang; Guoke Tang; Yuanzheng Ma
Journal:  BMC Complement Altern Med       Date:  2019-10-15       Impact factor: 3.659

3.  Puerarin Exerts Protective Effects on Wear Particle-Induced Inflammatory Osteolysis.

Authors:  Chao Yang; Juehong Li; Kechao Zhu; Xiangwei Yuan; Tao Cheng; Yebin Qian; Xianlong Zhang
Journal:  Front Pharmacol       Date:  2019-10-01       Impact factor: 5.810

Review 4.  Emerging Natural-Product-Based Treatments for the Management of Osteoarthritis.

Authors:  Maria-Luisa Pérez-Lozano; Annabelle Cesaro; Marija Mazor; Eric Esteve; Sabine Berteina-Raboin; Thomas M Best; Eric Lespessailles; Hechmi Toumi
Journal:  Antioxidants (Basel)       Date:  2021-02-09

Review 5.  Traditional Chinese Medicine Compound-Loaded Materials in Bone Regeneration.

Authors:  Guiwen Shi; Chaohua Yang; Qing Wang; Song Wang; Gaoju Wang; Rongguang Ao; Dejian Li
Journal:  Front Bioeng Biotechnol       Date:  2022-02-18

6.  Puerarin specifically disrupts osteoclast activation via blocking integrin-β3 Pyk2/Src/Cbl signaling pathway.

Authors:  Zuocheng Qiu; Ling Li; Yuying Huang; Keda Shi; Lizhong Zhang; Cuishan Huang; Jiechao Liang; Qingqiang Zeng; Jiali Wang; Xiangjiu He; Ling Qin; Xinluan Wang
Journal:  J Orthop Translat       Date:  2022-02-16       Impact factor: 5.191

7.  New use for old drug: Local delivery of puerarin facilitates critical-size defect repair in rats by promoting angiogenesis and osteogenesis.

Authors:  Huijuan Cao; Lingli Li; Ling Li; Xiangbo Meng; Yanzhi Liu; Wenxiang Cheng; Peng Zhang; Yongbo Gao; Ling Qin; Xinluan Wang
Journal:  J Orthop Translat       Date:  2022-07-31       Impact factor: 4.889

8.  Inhibitory Effect of Rosae Multiflorae Fructus Extracts on the Receptor Activator of NF-κB Ligand-Induced Osteoclastogenesis through Modulation of P38- and Ca2+-Mediated Nuclear Factor of Activated T-Cells Cytoplasmic 1 Expression.

Authors:  Keun Ha Park; Dong Ryun Gu; Min Seuk Kim; Seoung Hoon Lee
Journal:  J Bone Metab       Date:  2020-02-29

9.  MicroRNA-151a-3p Functions in the Regulation of Osteoclast Differentiation: Significance to Postmenopausal Osteoporosis.

Authors:  Yuehui He; Di Chen; Qian Guo; Pinghua Shi; Conglei You; Yanping Feng
Journal:  Clin Interv Aging       Date:  2021-07-14       Impact factor: 4.458

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.